| Budget Amount *help |
¥5,070,000 (Direct Cost: ¥3,900,000、Indirect Cost: ¥1,170,000)
Fiscal Year 2016: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2015: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2014: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
|
|---|
| Outline of Final Research Achievements |
We examined the relationship between cMet and Topoisomerase I lung cancer. Protein expression and phosphorylation of cMet using 10 lung cancer cell lines revealed high expression and hyperphosphorylation in 5 cell line.Expression and activity of Topo I were higher in cMet overexpressing cells and were related to the sensitivity of Topo I inhibitors. Inhibition of cMet by Met inhibitor also decreased Topo I. Upon examination of the downstream signaling, 29 candidate genes associated with Topo I expression were identified by cMet stimulation and suppression. In analysis using clinical donation, cMet nominated positive with 37.7% and TopoI at 51.3%, showing a significant correlation. This study suggests that cMet may regulate the expression of Topo I and we believe that it will bring important findings to establish future treatment strategies
|
